Instrument NameExelixis IncInstrument Symbol(EXEL-Q)

Instrument ExchangeNASDAQ

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – The surge in global cancer cases is raising...

EXEL earnings call for the period ending June 30, 2024.

USA News Group News Commentary – According to the American Cancer Society, 2024 will be the first year the USA expects to have more than 2 million new cancer cases. In order to respond to the rising rates of cancer, the National Cancer...

These stocks are both experts in their respective fields.

EXEL earnings call for the period ending March 31, 2024.

Phenomenal deals can still be found, even with the Nasdaq Composite climbing to a new all-time high.

These stocks are worth buying in most months of the year.

The growth-driven Nasdaq Composite has entered a new bull market, but plain-as-day deals can still be found.

You don't need to be a millionaire to get started. Investing on a budget can work, too.

The growth-driven Nasdaq Composite hasn't put the 2022 bear market entirely in the rearview mirror, which means opportunistic investors can still find bargains.

EXEL earnings call for the period ending December 31, 2023.

We are looking for U.S. companies with a history of robust free-cash-flow-to-capital

EXEL earnings call for the period ending September 30, 2023.

Bargains abound for growth-seeking investors, with the Nasdaq Composite still 20% below its record-closing high.

These three lesser-known biotech companies are profitable and growing revenue.

There is one key reason to consider the stock.

A 14% decline in the Nasdaq Composite represents the perfect opportunity for investors to pounce.

The best may be yet to come for these companies.

Both stocks have outperformed the broader market in the last 12 months.

These two companies make a compelling case for a high price.

As the IBB ETF nears a potential breakout, watch for strong performers like Regeneron Pharmaceuticals, Vertex, and Exelixis to continue outperforming.

EXEL earnings call for the period ending June 30, 2023.

The second-largest cause of death in the U.S., more than 600,000 deaths from cancer will occur in 2023. Learn about the best cancer stocks to invest in now.